Biotech companies typically develop deep research portfolios, but many promising early-stage projects don't progress if the team is stretched thin and focused on the lead asset.
To fully realize the value of projects under development, these companies need external support that is both senior-level and hands-on.
Pharmagellan offers just that: expert advice and project execution to biotech companies willing to discover how far they can go.
Preclinical, translational, and early clinical strategy and execution
Competitive and financial analysis of products, portfolios, and companies
We're hard at work on our book,
– the only source you'll need for biopharma forecasting and valuation.
• Comprehensive guide to financial assessment of development- and commercial-stage drugs, portfolios, and companies
• Up-to-date data, references, and "rules of thumb" for revenues, costs, risk adjustment, corporate finance, and more
• One-stop handbook for business development / finance professionals, investors, equity analysts, investment bankers, and consultants
For news, excerpts, and release / purchasing info, sign up for email updates below.